Gilead To Sell Cheaper Generic Version Of Hep C Drug As It Struggles To Compete In Market It Once Dominated
The company says that it's offering the generic treatment so that it can lower costs for patients, but skeptics say Gilead's expensive hepatitis C drugs has put them behind competitors who are offering much cheaper versions. Meanwhile, an Associated Press investigation finds that it's been mostly business as usual for pharma, despite President Donald Trump's vows to cut drugs costs.